Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

Johnson & Johnson Strengthens Pharmaceutical Position with New Therapeutics and Strategic M&A Moves

Johnson & Johnson’s recent pharmaceutical and biotech developments have reinforced its strategic footing in the industry, with a strong pipeline, proactive lifecycle management, and aggressive M&A posture positioning the company for long-term growth…

Lisa Martinez

22/09/2025, 07:35

4 minutes to read

Ipsen Secures Japanese Approval for Bylvay, Expanding Rare-Disease Reach

Ipsen SA has secured regulatory approval in Japan for its rare disease treatment Bylvay, expanding its commercial footprint in a market underserved for progressive familial intrahepatic cholestasis (PFIC) and related cholestatic disorders.

Lisa Martinez

20/09/2025, 11:38

4 minutes to read

AbbVie Navigates Patent Challenges and Expands Market Access with Strategic Moves

AbbVie Inc. has demonstrated resilience in the face of patent expirations and intensifying competition, with a strong market access strategy, pipeline diversification, and shareholder value preservation, positioning the company for sustained growth …

Lisa Martinez

18/09/2025, 08:18

4 minutes to read

GSK’s $30 Billion U.S. Investment: Aiming for Market Leadership and Innovation Amidst Industry Challenges

GlaxoSmithKline (GSK) has announced a $30 billion investment in the US over the next five years to enhance market access, innovation, and growth, positioning the company to compete with rivals in the pharmaceutical industry.

Lisa Martinez

17/09/2025, 11:58

5 minutes to read

Newer articles